MDxHealth Inks Japanese Partnership with Sumitomo Subsidiary | GenomeWeb

NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed a partnership with a subsidiary of Sumitomo to bring the firm's molecular diagnostics products to the Japanese market.

Liege, Belgium-based MDxHealth said that Sumitomo subsidiary Summit Pharmaceuticals International will market its pharmaco molecular diagnostic epigenetic technologies and products. Specifically, Summit will aim to provide companion diagnostics to pharmaceutical firms in the Japanese market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.